Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Plasma Cell Myeloma: early-phase trial registry
7 of 33 indexed Plasma Cell Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #463 of 28,707 conditions by registered trial count.
33 US clinical trials · 7 currently recruiting · #463 of 28,707 conditions by registered trial count
Plasma Cell Myeloma: 33 US clinical trials tracked, 7 recruiting.
Plasma Cell Myeloma is the subject of 33 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is Sanofi, running 4 of these trials.
Enrollment posture brief
Registry condition plasma-cell-myeloma
OPEN 7 | RECR 21% | LATE 6 | EARLY 17 | RANK #463 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Renal Impairment (21% recruiting · 33 trials)
Plasma Cell Myeloma lists 7 open slots (21% of 33 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Plasma Cell Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Plasma Cell Myeloma is recruiting below its size-band peers.
7 of 33 indexed trials (21.2%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Plasma Cell Myeloma trials is spread across many organizations.
Sanofi accounts for 4 of 33 trials (12.1%). 17 distinct sponsors appear on at least one study for this condition label.
-
Typical Plasma Cell Myeloma enrolment sits around 73 participants.
Median target enrolment is 73 among the 33 trials that report a genuine target (sentinel values excluded). 18 of those (54.5%) plan for fewer than 100 participants.
-
Plasma Cell Myeloma research is mostly interventional.
28 interventional and 5 observational studies make up this index (84.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
33 total, page 1 of 1
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
ECOG-ACRIN Cancer Research Group
NCT04566328
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
NCT05561387
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Roswell Park Cancer Institute
NCT05312255
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
University of Southern California
NCT03858205
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
NCT05011045
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
Emory University
NCT05208307
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
Robert Flavell, MD, PhD
NCT05892393
Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
ECOG-ACRIN Cancer Research Group
NCT01863550
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Sanofi
NCT04458831
A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sanofi
NCT03319667
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
City of Hope Medical Center
NCT04537871
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
NCT04270409
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
M.D. Anderson Cancer Center
NCT03141437
Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
M.D. Anderson Cancer Center
NCT02420860
Lenalidomide Maintenance in Plasma Cell Myeloma
Memorial Sloan Kettering Cancer Center
NCT02538198
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
US Oncology Research
NCT04782687
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
NCT05669989
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
GeoVax
NCT04977024
Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission
Memorial Sloan Kettering Cancer Center
NCT04221178
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Emory University
NCT03942224
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
Mayo Clinic
NCT05392946
Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
City of Hope Medical Center
NCT03346135
Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma
Emory University
NCT03756896
SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy
Roswell Park Cancer Institute
NCT02334865
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
Roswell Park Cancer Institute
NCT04876248
S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma
SWOG Cancer Research Network
NCT00900263
Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy
Emory University
NCT03078452
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
NCT01864018
DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer
Barbara Ann Karmanos Cancer Institute
NCT04282343
Home Based Daratumumab Administration for Patients With Multiple Myeloma
Thomas Jefferson University
NCT05511428
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
Jason Valent
NCT02057640
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Fred Hutchinson Cancer Center
NCT01503242
Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma
Mayo Clinic
NCT02492750
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 10 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Plasma Cell Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Plasma Cell Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Plasma Cell Myeloma page
33 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Plasma Cell Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sanofi sponsors the most Plasma Cell Myeloma trials on record, review their full trial history before evaluating a specific study. See Sanofi's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Plasma Cell Myeloma condition card totals 33 registered trials; most-linked intervention Dexamethasone; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.